SWM
ATXS

Spire Wealth Management’s Astria Therapeutics ATXS Stock Holding History

Spire Wealth Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-500
Closed -$9K – 2596
2021
Q1 		$9K Buy
+500
New +$9.03K ﹤0.01% 2433

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Spire Wealth Management's ATXS Position: Q2 2021 in Review

Spire Wealth Management sold out of Astria Therapeutics (ATXS) in Q2 2021, closing a stake of 500 shares — an estimated $9K sold.

Spire Wealth Management first reported a position in ATXS in Q1 2021 and held it in 1 quarter. The position peaked at $9K in Q1 2021. 58 funds tracked by Wall St. Rank hold ATXS as of Q2 2021.

  • Spire Wealth Management reported no remaining Astria Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Spire Wealth Management sold 500 Astria Therapeutics shares in Q2 2021, an estimated $9K.
  • Spire Wealth Management first reported a position in Astria Therapeutics in Q1 2021 and held it in 1 quarter.
  • Spire Wealth Management's Astria Therapeutics position peaked at $9K in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2021.

Based on Spire Wealth Management's 13F filing for Q2 2021, filed 26 Jul 2021.